GAMUT - The Grieg Academy Music Therapy Research Centre, NORCE Norwegian Research Centre, Bergen, Norway.
Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, Catania, Italy.
Cochrane Database Syst Rev. 2022 May 9;5(5):CD004381. doi: 10.1002/14651858.CD004381.pub4.
BACKGROUND: Social interaction and social communication are among the central areas of difficulty for autistic people. Music therapy uses music experiences and the relationships that develop through them to enable communication and expression, thus attempting to address some of the core problems of autistic people. Music therapy has been applied in autism since the early 1950s, but its availability to autistic individuals varies across countries and settings. The application of music therapy requires specialised academic and clinical training which enables therapists to tailor the intervention to the specific needs of the individual. The present version of this review on music therapy for autistic people is an update of the previous Cochrane review update published in 2014 (following the original Cochrane review published in 2006). OBJECTIVES: To review the effects of music therapy, or music therapy added to standard care, for autistic people. SEARCH METHODS: In August 2021, we searched CENTRAL, MEDLINE, Embase, eleven other databases and two trials registers. We also ran citation searches, checked reference lists, and contacted study authors to identify additional studies. SELECTION CRITERIA: All randomised controlled trials (RCTs), quasi-randomised trials and controlled clinical trials comparing music therapy (or music therapy alongside standard care) to 'placebo' therapy, no treatment, or standard care for people with a diagnosis of autism spectrum disorder were considered for inclusion. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodological procedures. Four authors independently selected studies and extracted data from all included studies. We synthesised the results of included studies in meta-analyses. Four authors independently assessed risk of bias (RoB) of each included study using the original RoB tool as well as the certainty of evidence using GRADE. MAIN RESULTS: We included 16 new studies in this update which brought the total number of included studies to 26 (1165 participants). These studies examined the short- and medium-term effect of music therapy (intervention duration: three days to eight months) for autistic people in individual or group settings. More than half of the studies were conducted in North America or Asia. Twenty-one studies included children aged from two to 12 years. Five studies included children and adolescents, and/or young adults. Severity levels, language skills, and cognition were widely variable across studies. Measured immediately post-intervention, music therapy compared with 'placebo' therapy or standard care was more likely to positively effect global improvement (risk ratio (RR) 1.22, 95% confidence interval (CI) 1.06 to 1.40; 8 studies, 583 participants; moderate-certainty evidence; number needed to treat for an additional beneficial outcome (NNTB) = 11 for low-risk population, 95% CI 6 to 39; NNTB = 6 for high-risk population, 95% CI 3 to 21) and to slightly increase quality of life (SMD 0.28, 95% CI 0.06 to 0.49; 3 RCTs, 340 participants; moderate-certainty evidence, small to medium effect size). In addition, music therapy probably results in a large reduction in total autism symptom severity (SMD -0.83, 95% CI -1.41 to -0.24; 9 studies, 575 participants; moderate-certainty evidence). No clear evidence of a difference between music therapy and comparison groups at immediately post-intervention was found for social interaction (SMD 0.26, 95% CI -0.05 to 0.57, 12 studies, 603 participants; low-certainty evidence); non-verbal communication (SMD 0.26, 95% CI -0.03 to 0.55; 7 RCTs, 192 participants; low-certainty evidence); and verbal communication (SMD 0.30, 95% CI -0.18 to 0.78; 8 studies, 276 participants; very low-certainty evidence). Two studies investigated adverse events with one (36 participants) reporting no adverse events; the other study found no differences between music therapy and standard care immediately post-intervention (RR 1.52, 95% CI 0.39 to 5.94; 1 study, 290 participants; moderate-certainty evidence). AUTHORS' CONCLUSIONS: The findings of this updated review provide evidence that music therapy is probably associated with an increased chance of global improvement for autistic people, likely helps them to improve total autism severity and quality of life, and probably does not increase adverse events immediately after the intervention. The certainty of the evidence was rated as 'moderate' for these four outcomes, meaning that we are moderately confident in the effect estimate. No clear evidence of a difference was found for social interaction, non-verbal communication, and verbal communication measured immediately post-intervention. For these outcomes, the certainty of the evidence was rated as 'low' or 'very low', meaning that the true effect may be substantially different from these results. Compared with earlier versions of this review, the new studies included in this update helped to increase the certainty and applicability of this review's findings through larger sample sizes, extended age groups, longer periods of intervention and inclusion of follow-up assessments, and by predominantly using validated scales measuring generalised behaviour (i.e. behaviour outside of the therapy context). This new evidence is important for autistic individuals and their families as well as for policymakers, service providers and clinicians, to help in decisions around the types and amount of intervention that should be provided and in the planning of resources. The applicability of the findings is still limited to the age groups included in the studies, and no direct conclusions can be drawn about music therapy in autistic individuals above the young adult age. More research using rigorous designs, relevant outcome measures, and longer-term follow-up periods is needed to corroborate these findings and to examine whether the effects of music therapy are enduring.
背景:社交互动和社交沟通是自闭症患者的核心障碍之一。音乐治疗利用音乐体验和通过这些体验发展的关系,使人们能够进行交流和表达,从而试图解决自闭症患者的一些核心问题。自 20 世纪 50 年代初以来,音乐治疗已在自闭症领域得到应用,但在不同国家和环境中,自闭症患者获得音乐治疗的机会有所不同。音乐治疗的应用需要专门的学术和临床培训,使治疗师能够根据个体的具体需求调整干预措施。本综述是对之前发表的 Cochrane 综述(发表于 2006 年)的更新,是对自闭症人群音乐治疗的更新综述。
目的:评价音乐治疗或音乐治疗联合标准护理对自闭症患者的效果。
检索方法:2021 年 8 月,我们检索了 Cochrane 图书馆、MEDLINE、Embase 等 11 个数据库和 2 个试验注册库。我们还进行了引文搜索,检查了参考文献列表,并联系了研究作者以确定其他研究。
纳入排除标准:所有随机对照试验(RCT)、准随机试验和对照临床试验,比较音乐治疗(或音乐治疗联合标准护理)与安慰剂治疗、无治疗或自闭症谱系障碍患者的标准护理,均纳入研究。
数据收集与分析:我们使用标准的 Cochrane 方法学程序。四名作者独立选择研究,并从所有纳入研究中提取数据。我们对纳入研究进行了荟萃分析。四名作者独立使用原始偏倚风险工具以及 GRADE 评估每个纳入研究的证据确定性。
主要结果:本更新纳入了 16 项新研究,使纳入研究总数达到 26 项(1165 名参与者)。这些研究考察了个体或小组环境中音乐治疗(干预持续时间:3 天至 8 个月)对自闭症患者的短期和中期效果。超过一半的研究在美国或亚洲进行。21 项研究纳入了 2 至 12 岁的儿童。5 项研究纳入了儿童和青少年,和/或青年。研究中严重程度水平、语言技能和认知能力差异很大。与安慰剂治疗或标准护理相比,音乐治疗干预后更有可能显著改善整体改善(风险比(RR)1.22,95%置信区间(CI)1.06 至 1.40;8 项研究,583 名参与者;中等确定性证据;低风险人群的额外获益治疗需要数(NNTB)为 11,95%CI 为 6 至 39;高风险人群的 NNTB 为 6,95%CI 为 3 至 21),并略微提高生活质量(SMD 0.28,95%CI 0.06 至 0.49;3 项 RCT,340 名参与者;中等确定性证据,小到中效应量)。此外,音乐治疗可能会使自闭症患者的总体症状严重程度显著降低(SMD-0.83,95%CI-1.41 至-0.24;9 项研究,575 名参与者;中等确定性证据)。在干预后立即评估时,音乐治疗与对照组之间在社交互动(SMD 0.26,95%CI-0.05 至 0.57,12 项研究,603 名参与者;低确定性证据)、非言语沟通(SMD 0.26,95%CI-0.03 至 0.55;7 项 RCT,192 名参与者;低确定性证据)和言语沟通(SMD 0.30,95%CI-0.18 至 0.78;8 项研究,276 名参与者;非常低确定性证据)方面没有明显差异。两项研究调查了不良事件,其中一项(36 名参与者)报告无不良事件;另一项研究发现音乐治疗与标准护理在干预后立即没有差异(RR 1.52,95%CI 0.39 至 5.94;1 项研究,290 名参与者;中等确定性证据)。
作者结论:本更新综述的结果提供了证据,表明音乐治疗可能与自闭症患者整体改善的机会增加相关,可能有助于他们改善自闭症总体严重程度和生活质量,并且可能不会增加干预后立即出现的不良事件。这些四个结局的证据确定性被评为“中等”,这意味着我们对效应估计有中等程度的信心。在干预后立即评估时,在社交互动、非言语沟通和言语沟通方面没有发现明显差异。对于这些结局,证据确定性被评为“低”或“非常低”,这意味着真实效应可能与这些结果有很大不同。与之前的版本相比,本更新纳入的新研究通过更大的样本量、更长的干预时间和纳入随访评估、以及主要使用测量一般行为(即治疗环境之外的行为)的有效量表,增加了本综述发现的确定性和适用性。这些新证据对于自闭症患者及其家属以及决策者、服务提供者和临床医生都很重要,有助于确定应该提供的干预类型和数量,并规划资源。研究结果的适用性仍然局限于研究中纳入的年龄组,并且不能直接得出关于成年后自闭症患者音乐治疗的结论。需要使用严格的设计、相关的结局测量和更长的随访期来进一步证实这些发现,并研究音乐治疗的效果是否持久。
Cochrane Database Syst Rev. 2022-5-9
Cochrane Database Syst Rev. 2021-10-12
Cochrane Database Syst Rev. 2022-8-25
Cochrane Database Syst Rev. 2018-3-1
Cochrane Database Syst Rev. 2022-6-29
Cochrane Database Syst Rev. 2022-11-11
Cochrane Database Syst Rev. 2025-1-29
Cochrane Database Syst Rev. 2018-5-8
Cochrane Database Syst Rev. 2021-9-14
Cochrane Database Syst Rev. 2022-11-17
Autism Adulthood. 2021-3-1
J Child Psychol Psychiatry. 2021-2